Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-adapted FDG-PET guided first-line therapy in advanced Hodgkin lymphoma
2007-006064-30Phase 3Unknown
- Sponsor
- University College London
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, bleomycin, vinblastine, dacarbazine, cyclophosphamide and 4 more in Hodgkin lymphoma (HL) (2 arms), sponsored by University College London. Primary endpoint: FDG-PET-guided early response assessment. Status: unknown.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazinecyclophosphamide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2007-006064-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006064-30.